Cellmed Cancer Treatment Solution

Cellmed from Vienna, Austria is a research company in cancer treatment with cellular immunotherapy with their lead product Procure. Procure is a vaccine manufactured from cells isolated from the individual patient. Precursor cells collected from the patient via leukapheresis are differentiated into dendritic cells, loaded with two universal tumor antigens. This unique dual antigen loading technology of Procure is designed to elicit both short- and long-term anti-tumor immune responses and targets two fundamental and well characterized structures essential for tumor progression and development.